Replies to post #3130 on Intellicell Biosciences Inc (fka SVFC)

[Nadendla]

I think MERCK is going to invest heavily into INTELLICELL..Thats One Powerful partner with influence WorldWide ...Love the interest MERCK has in INTELLICELL...Makes it more Obvious when WILSON TAWE is already sitting on INTELLICELL's Board..

MERCK subsidiary Millipore collaborating with Intellicell Biosciences..Millipore(American Subsidiary of MERCK)has executed an exclusive supply and sale agreement with IntelliCell BioSciences to sell and distribute the guava flow cytometry platform into the area of SVF..

http://www.cpreports.com/2011/11/20/market-alert-ray-dirks-research-report-on-intellicell-biosciences-svfc-november-21-2011/


Here is Wilson Tawe, PhD, MBA Manager - Instrument FAS (North America) @ EMD Millipore(American Subsidiary of MERCK) sitting on the Board of Advisors..

http://www.intellicellbiosciences.com/corporate-profile.html

Medical Board of Advisors


Dr. James Andrews, The Andrews Institute
Dr. Harold Bafitis, The Plastic Surgery Institute of The Palm Beaches
Dr. Peter Bruno, Internist, New York City
Dr. Greg Cavaliere, Orthopedic Surgeon, NY Rangers
Dr. Gil Chimes DC, DICBN, CCSP, CSCS Greenwich Sports Medicine in Greenwich, CT
Dr. Sydney Coleman, Tribeca Plastic Surgery, New York City
Dr. Mathew Cooper Aventura Chiropractor, Aventura, FL
Dr. Alberto Goldman, Plastic Surgeon, Brazil
Dr. Joshua Hackel, The Andrews Institute
Dr. Anthony V. Maddalo, Orthopedic Surgeon, NY Rangers
Dr. Frederick Nicola, D.I.S.C. Sports & Spine Center, Marian del Rey, Oakland/LA Raiders
Dr. Eric Richter, Neurologist, Chief LSU Health Sciences Center
Wilson Tawe, PhD, MBA Manager - Instrument FAS (North America) @ EMD Millipore
Dr. Nicholas Toscano, Periodontist, Editor in Chief JIAD
Mr. Kevin Wilk, PT, DPT The Andrews Institute

EMD Millipore is a division of Merck KGaA, Darmstadt, Germany

http://www.millipore.com/company/flx4/about

https://lists.purdue.edu/pipermail/cytometry/2012-February/042840.html

Headquartered in Billerica, Massachusetts, EMD Millipore has some 10,000 employees in 67 countries motivated by the potential of science for life through a portfolio of more than 40,000 products. Comprised of three business units—Bioscience, Lab Solutions, and Process Solutions— EMD Millipore is a top tier supplier to the life science industry, and serves as a strategic partner for scientists, engineers, and researchers. For more information on the EMD Millipore portfolio, vision and mission, as well as careers, events and current news, refer to our divisional section.


EMD Millipore Headquarters
290 Concord Road
Billerica, MA 01821
978.715.4321
The EMD Group

EMD Millipore is part of the The EMD Group, a global pharmaceutical and chemical company which generated total revenues of EUR 9.3 billion in 2010 and has 40,000 dedicated employees worldwide. In North America, Merck, Darmstadt, Germany operates under the umbrella brand EMD (EMD Millipore), formed from the initials of Emanuel Merck, Darmstadt.

[seattle1980]

WOW...GREAT NEWS INDEED...

GOOOOOOOOOOOOOOOOOOOOOOOOOO$$$$$$$$$$$$$$$$$$$$$ SVFC bank

[cjstocksup]

SVFC associations with Merck, Roche and so many others is undeniable and shows just what a huge bio pharma company we are becoming. It was not long ago we were trading on the Nasdaq. The email replies from the company stated they are looking at options to getting back on the big boards next. Looking sweet. Shares below .05 and .10 will not be around for long.

[Papa Bear]

SVFC: AWESOME NEWS UPDATE !!!! BIG THINGS HAPPENING HERE VERY SOON !:-)

No bigger news than this IMO

IntelliCell's stem cell technology validated by Merck study
by Deborah Sterescu
IntelliCell BioSciences (OTCQB:SVFC) said Thursday that its technology used to generate fat, or adipose, stem cells was tested by a division of healthcare giant Merck, with positive results.
Fat stem cells are now the cutting edge, with many doctors and companies researching the use of them for the treatment of arthritis, as well as a host of orthpedic injuries, and congestive heart failure, gum recession, wound healing, along with a several other ailments.
IntelliCell has developed an in-house technology where it can process stromal vascular fraction (SVF) cells containing a high concentration of adipose stem cells. The company believes that it is currently the only one that does not use enzymes in processing adipose tissue, and actually counts and checks the adipose stem cells they manufacture.
The company's technique takes approximately 30 minutes, and the stem cells can be returned to the doctor in the same day.
Millipore, owned by Merck, performed an antibody flow cytometry study of IntelliCell's technology, which showed that the company's manufactured cells yielded an average of 10 times the number of SVF cells containing adult adipose stem cells, from less fat than that which the IntelliCell believes is used by an of its competition using enzymes in their process.
The study also showed that IntelliCell's cells contain all of the viable cells that are manufactured by competing technologies.
"We believe IntelliCell is setting the gold standard for adipose stem cell processing without the use of enzymes and yielding high number of SVFs with adult adipose stem cell counts," said IntelliCell chairman and CEO, Dr. Steven Victor.
"We feel that our technology is a true game changer in the field of regenerative medicine and that SVF could show incredible promise for a wide range of clinical uses in the near future.
"We believe that the body stores all of the reparative and regenerative cells it could possibly need as a result of trauma or illness in the stromal vascular fraction (SVF) contained in the fat."
Indeed, these fat stem cells have similar potential to embryonic stem cells in their pluripotency, in vast number, from a source that involves no moral or ethical issues, as well as no chemical additives required for digestion of the tissue.
In the aesthetic world, the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the US FDA published its laws on autologous stem cells in mid-2009, the field has expanded rapidly.
IntelliCell has established processing centers in New York City, Philadelphia, Dallas/Ft. Worth, and New Orleans, and has entered into a licensing agreement for a center in Palm Beach.

[cjstocksup]

No bigger news than this IMO

IntelliCell's stem cell technology validated by Merck study
by Deborah Sterescu
IntelliCell BioSciences (OTCQB:SVFC) said Thursday that its technology used to generate fat, or adipose, stem cells was tested by a division of healthcare giant Merck, with positive results.
Fat stem cells are now the cutting edge, with many doctors and companies researching the use of them for the treatment of arthritis, as well as a host of orthpedic injuries, and congestive heart failure, gum recession, wound healing, along with a several other ailments.
IntelliCell has developed an in-house technology where it can process stromal vascular fraction (SVF) cells containing a high concentration of adipose stem cells. The company believes that it is currently the only one that does not use enzymes in processing adipose tissue, and actually counts and checks the adipose stem cells they manufacture.
The company's technique takes approximately 30 minutes, and the stem cells can be returned to the doctor in the same day.
Millipore, owned by Merck, performed an antibody flow cytometry study of IntelliCell's technology, which showed that the company's manufactured cells yielded an average of 10 times the number of SVF cells containing adult adipose stem cells, from less fat than that which the IntelliCell believes is used by an of its competition using enzymes in their process.
The study also showed that IntelliCell's cells contain all of the viable cells that are manufactured by competing technologies.
"We believe IntelliCell is setting the gold standard for adipose stem cell processing without the use of enzymes and yielding high number of SVFs with adult adipose stem cell counts," said IntelliCell chairman and CEO, Dr. Steven Victor.
"We feel that our technology is a true game changer in the field of regenerative medicine and that SVF could show incredible promise for a wide range of clinical uses in the near future.
"We believe that the body stores all of the reparative and regenerative cells it could possibly need as a result of trauma or illness in the stromal vascular fraction (SVF) contained in the fat."
Indeed, these fat stem cells have similar potential to embryonic stem cells in their pluripotency, in vast number, from a source that involves no moral or ethical issues, as well as no chemical additives required for digestion of the tissue.
In the aesthetic world, the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the US FDA published its laws on autologous stem cells in mid-2009, the field has expanded rapidly.
IntelliCell has established processing centers in New York City, Philadelphia, Dallas/Ft. Worth, and New Orleans, and has entered into a licensing agreement for a center in Palm Beach.

[cjstocksup]

No bigger news than this IMO

IntelliCell's stem cell technology validated by Merck study
by Deborah Sterescu
IntelliCell BioSciences (OTCQB:SVFC) said Thursday that its technology used to generate fat, or adipose, stem cells was tested by a division of healthcare giant Merck, with positive results.
Fat stem cells are now the cutting edge, with many doctors and companies researching the use of them for the treatment of arthritis, as well as a host of orthpedic injuries, and congestive heart failure, gum recession, wound healing, along with a several other ailments.
IntelliCell has developed an in-house technology where it can process stromal vascular fraction (SVF) cells containing a high concentration of adipose stem cells. The company believes that it is currently the only one that does not use enzymes in processing adipose tissue, and actually counts and checks the adipose stem cells they manufacture.
The company's technique takes approximately 30 minutes, and the stem cells can be returned to the doctor in the same day.
Millipore, owned by Merck, performed an antibody flow cytometry study of IntelliCell's technology, which showed that the company's manufactured cells yielded an average of 10 times the number of SVF cells containing adult adipose stem cells, from less fat than that which the IntelliCell believes is used by an of its competition using enzymes in their process.
The study also showed that IntelliCell's cells contain all of the viable cells that are manufactured by competing technologies.
"We believe IntelliCell is setting the gold standard for adipose stem cell processing without the use of enzymes and yielding high number of SVFs with adult adipose stem cell counts," said IntelliCell chairman and CEO, Dr. Steven Victor.
"We feel that our technology is a true game changer in the field of regenerative medicine and that SVF could show incredible promise for a wide range of clinical uses in the near future.
"We believe that the body stores all of the reparative and regenerative cells it could possibly need as a result of trauma or illness in the stromal vascular fraction (SVF) contained in the fat."
Indeed, these fat stem cells have similar potential to embryonic stem cells in their pluripotency, in vast number, from a source that involves no moral or ethical issues, as well as no chemical additives required for digestion of the tissue.
In the aesthetic world, the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the US FDA published its laws on autologous stem cells in mid-2009, the field has expanded rapidly.
IntelliCell has established processing centers in New York City, Philadelphia, Dallas/Ft. Worth, and New Orleans, and has entered into a licensing agreement for a center in Palm Beach.